当前位置:首页 > 报告详情

橙皮书药品上市-Quach.pdf

上传人: 哆哆 编号:631117 2025-04-19 19页 271.94KB

1、Orange Book Drug Marketing StatusTruong Quach,PharmDLead PharmacistOffice of Generic Drugs Office of Generic Drug Policy Division of Orange Book Publication and Regulatory Assessment(DOBPRA)CDER|U.S.FDAGeneric Drug Forum April 10th,2024fda.gov/cdersbiafda.gov/cdersbia2 Present a brief history of the

2、 Orange Book Describe the basics of marketing status changes Describe 506I marketing status report requirements Discuss three case studies on 506I marketingObjectivesfda.gov/cdersbiafda.gov/cdersbia31980 1stOrange Book Edition publication1984 Passage of the Drug Price Competition and Patent Term Res

3、toration Act(Hatch-Waxman Amendments)Approved prescription drug products with therapeutic equivalence evaluation1985 6thEdition of the Orange Book annual publicationFDA began identifying discontinued drug products in the Prescription Drug Product List section in the Orange Book1987 7thEdition of the

4、 Orange Book annual publicationA distinct Discontinued Drug Product List(Discontinued Section)was created in the Orange Book publicationBackground of the Publicationfda.gov/cdersbiafda.gov/cdersbia4 1.11 Discontinued Section 1.12 Changes to the Orange BookOrange Book Prefacefda.gov/cdersbiafda.gov/c

5、dersbia5When and how often is the Orange Book updated?Information is updated by website and as downloadable PDFs.Updates are made daily,semi-monthly,monthly and annual basisWhat information is included in the updates?Daily website updates:patent information and new generic drug approvals Semi-monthl

6、y website:all changes which occurred in the current month.Monthly data files update consist of all changes to Orange Book which occurred in the prior month.Print Annual Edition of Orange Book consist of full copy of all the changes in the Orange Book which occurred in the prior year.Publication Freq

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
本文介绍了美国食品药品监督管理局(FDA)的橙皮书,它是一本包含已批准处方药产品及其 therapeutic equivalence evaluation 的出版物。橙皮书的历史可追溯至1980年首版,1984年Hatch-Waxman修正案通过后,它开始列出具有治疗等效性评估的批准处方药产品。1985年,FDA开始在橙书中标识已停产的药物产品。1987年,橙书特设停产药物产品列表。 橙书的更新频率是根据FDA Reauthorization Act of 2017中新增的506I条款规定的。506I要求药品赞助商在药品上市前通知FDA关于上市状态的变更。这些变更可能包括停产或重新上市。通知需要包括药品的NDC、名称、NDA或ANDA号码、强度、预计不再销售或可销售日期以及停止销售的原因。 文中还提供了三个案例研究,详细说明了506I报告的要求和FDA如何处理这些报告。例如,一个案例中,一个ANDA在停产但计划重新上市时,未能及时提交506I通知,导致产品被移至停产部分,直到提交并批准了PAS后才被返回激活部分。 总之,橙皮书提供了一个关于已批准药物产品及其上市状态的重要资源,而506I条款的加入加强了对药品上市状态变更的管理。
"Orange Book的历史及作用是什么?" "506I报告的要求有哪些?案例分析如何?" "如何获取最新的Orange Book信息?"
客服
商务合作
小程序
服务号
折叠